email article
Complex gastrointestinal (GI) cancer surgery had less risk of postoperative adverse outcomes when supported by anesthesiologists performing a high annual volume of certain procedures, a large Canadian population-based study found.
Care by high-volume anesthesiologists was independently associated with 15% lower odds of combined 90-day major morbidity (including mortality) and readmission, after adjustment for patient case mix, institutional volume, and surgeon volume, reported Julie Hallet, MD, of the University of Toronto, and colleagues.
The primary outcome a composite of major 90-day morbidity (Clavien-Dindo 3-5) with readmission occurred in 36.3% of patients in the high-volume group (cutoff point of six or more procedures per year or ranking in the 75th percentile) and 45.7% of patients in the low-volume group, they stated in
This article is a collaboration between MedPage Today and:
Almost 40% of progressive, advanced gastrointestinal (GI) tumors with mismatch repair deficiency (dMMR) responded to the investigational anti-PD-1 agent dostarlimab, according to a preliminary clinical trial.
Overall, 38.7% of 106 patients responded to single-agent treatment with monoclonal antibody, including 36.2% of colorectal cancers (CRC) and 43.2% of all other tumors, which were primarily GI in origin. About three-fourths of patients had some degree of tumor shrinkage. During a median follow-up exceeding 1 year, median duration of response had yet to be reached.
Dostarlimab was well tolerated, as fewer than 10% of patients had ≥3 treatment-related adverse events (TRAEs), reported Thierry Andre, MD, of Sorbonne University and Saint-Antoine Hospital in Paris, at the Gastrointestinal Cancers Symposium virtual meeting.